Stevanato Group S.p.A.
Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries. The company focuses on drug containment, drug delivery, and diagnostic solutions, supplying products and services used across development, clinical, and commercial stages of the drug life cycle. Its portfolio includes containment systems such as vials, cartridges, syringes, and ampoules, alongside drug delivery devices, diagnostic consumables, analytical services, and medical devices. Stevanato Group also offers engineering capabilities through visual inspection, assembling, packaging, and glass-forming machinery, supporting manufacturing and packaging operations for biopharma customers. Headquartered in Piombino Dese, Italy, the company serves a global customer base across multiple healthcare and diagnostic markets.
$18.90
-$0.35 (-1.82%)
EOD Oct 16, 2026
16.76% operating margin is respectable but not wide. ROIC at 7.76%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 7.4%, steady but not accelerating.
At 35x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Net debt of €338M represents 30.6x FCF, leverage limits flexibility.
35.0x earnings. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1.23B
▲ +7.4% YoY
Net Income (TTM)
€135M
▲ +18.7% YoY
Op. Margin
17.37%
▲ +2.2pp YoY
ROIC
7.76%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€31M
▲ +107.0% YoY
Op. Cash Flow (TTM)
€249M
▲ +28.6% YoY
Net Debt
€338M
Cash & Equiv.
€131M
3Y CAGR: +6.4%
Continue Research
Is Stevanato Group S.p.A. (STVN) overvalued?
At a P/E of 35.0, Stevanato Group S.p.A. (STVN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Stevanato Group S.p.A. scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.4%; see dividend safety for coverage and history. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Stevanato Group S.p.A. a high-quality business?+
Stevanato Group S.p.A. scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 17.4% operating margin and a 7.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Does Stevanato Group S.p.A. (STVN) pay a dividend, and how much?+
Yes, Stevanato Group S.p.A. pays a regular dividend of about €0.06 per share per year (typically in quarterly installments), a yield of roughly 0.4% at the current price. That is a payout ratio of about 12.6% of earnings, so the dividend is amply covered by earnings. Stevanato Group S.p.A. has grown the dividend at roughly 6.5% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For STVN's full payout history, growth streak and dividend-safety score, see the dividends tab.
Is Stevanato Group S.p.A. a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh STVN's valuation and scores 15/100 on quality (lower-quality). It also yields about 0.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Instruments & Supplies
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.